Jazz Pharmaceuticals is proud to offer a two-part webinar series designed to help you identify epileptic symptoms and discover a form of treatment that is FDA approved.

Part 1: September 9 @ 3 PM ET

EPIDIOLEX® (cannabidiol) Oral Solution for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex in LTC

Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), tuberous sclerosis complex (TSC) are rare and severe epileptic encephalopathies with onset in infancy or early childhood. EPIDIOLEX®, a pharmaceutical formulation of highly purified cannabidiol (CBD) is FDA-approved for the treatment of seizures associated with LGS, DS, and TSC in patients ≥1 year of age.

Learning Objectives:

• Understand the characteristics and distinguishing features of Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous sclerosis complex, including clinical presentations and diagnostic criteria.
• Describe the differences in cannabis products and how EPIDIOLEX® is distinct.
• Summarize the findings of the EPIDIOLEX® randomized controlled trials in the treatment of seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous sclerosis complex.
• Review essential information provided in the EPIDIOLEX® labeling to understand its indications, usage, and safety.

Speaker info: Aisha Fowler, Associate Director of Payer, Value, and Outcomes (PVO) at Jazz Pharmaceuticals, Aisha leads scientific engagement across Jazz therapeutic areas, focusing on marketed and pipeline products, while cultivating relationships with regional payer and long-term care accounts. Aisha earned her Doctor of Pharmacy (PharmD) from The University of Texas at Austin, where she gained valuable experience in long-term care pharmacies specializing in Intellectual and Developmental Disability (IDD) communities.

Part 2: September 30 @ 3 PM ET

Overview of Rare Refractory Epilepsy Syndromes & the REST-LGS Screening Tool

Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), tuberous sclerosis complex (TSC) are rare and severe epileptic encephalopathies with onset in infancy or early childhood. EPIDIOLEX®, a pharmaceutical formulation of highly purified cannabidiol (CBD) is FDA-approved for the treatment of seizures associated with LGS, DS, and TSC in patients ≥1 year of age.

Learning Objectives:

• Review epidemiology, clinical presentation, and diagnosis of Lennox-Gastaut Syndrome (LGS).
  Gain familiarity with the Refractory Epilepsy Screening Tool (REST-LGS) for recognizing Lennox-Gastaut syndrome in both clinical and long-term care settings.
• Discuss data from the BECOME (BEhavior, COgnition, and More with EPIDIOLEX®) Caregiver Survey, including real-world seizure and non-seizure outcomes in pediatric and adult patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS).

Speaker info: Aisha Fowler, Associate Director of Payer, Value, and Outcomes (PVO) at Jazz Pharmaceuticals, Aisha leads scientific engagement across Jazz therapeutic areas, focusing on marketed and pipeline products, while cultivating relationships with regional payer and long-term care accounts. Aisha earned her Doctor of Pharmacy (PharmD) from The University of Texas at Austin, where she gained valuable experience in long-term care pharmacies specializing in Intellectual and Developmental Disability (IDD) communities.